TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04771377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplementation
Description: protein supplements will be supplied to participants at no cost physical activity Will be performed virtually by PT
Study: NCT00848484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK5757
Description: This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
Study: NCT01587482

Intervention type: PROCEDURE
Intervention: PacLitaxel Eluting Balloon Application
Description: Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
Study: NCT03151746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill administered orally 1 hour before planned surgical procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
Study: NCT00758342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% + Brinzolamide 1.0%
Description: Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travoprost 0.004% + Tears Natural
Description: Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
Study: NCT03473210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniopatch
Description: a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
Study: NCT01937169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Task
Description: A motor task executed for 30 minutes after drug adminidtration

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Motor Task
Description: A motor task executed for 30 minutes after drug adminidtration

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Levodopa tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa tablet

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham non-motor task
Description: A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Study: NCT00267098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Biventricular pacing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization Therapy (CRT)
Description: Right ventricular pacing
Study: NCT01225497

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard eccentric exercise
Description: Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise-Experimental group
Description: Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
Study: NCT04623606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BOOST cells
Description: Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
Study: NCT03135990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Virtual Reality Technology
Description: Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
Study: NCT02853487

Intervention type: DEVICE
Intervention: Actigraphy
Description: An actigraph from Philips

Intervention type: DEVICE
Intervention: Actigraphy
Description: An actigraph from Philips

Intervention type: OTHER
Intervention: Diary
Description: Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.

Intervention type: OTHER
Intervention: Diary
Description: Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
Study: NCT03400683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 microgram misoprostol in sublingual every four hours for a maximum of five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 microgram misoprostol in sublingual every four hours for a maximum of five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 200 microgram misoprostol in sublingual every four hours for a maximum of five doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: 15mg( letrozole 2.5mg) on three successive day

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's catheter
Description: transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions
Study: NCT00891033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
Study: NCT00463853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CABG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CMRI
Study: NCT03194997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
Study: NCT01246089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab injection
Description: Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
Study: NCT02633436

Intervention type: OTHER
Intervention: SLC1A5 expression
Description: To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.

Intervention type: OTHER
Intervention: SLC1A5 expression
Description: To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
Study: NCT01075477

Intervention type: DRUG
Intervention: rituximab [Mabthera/Rituxan]
Description: As prescribed by physician
Study: NCT00727740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
Study: NCT02263807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MPFL Group
Description: MPFL reconstruction or standard treatment followed by physiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Arthroscopy followed by active rehabilitation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: Arthroscopy followed by active rehabilitation
Study: NCT04417205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Rich Breakfast
Description: Participants will be asked to consume the provided carbohydrate rich breakfast before 1000h daily for 28 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein enriched breakfast
Description: Participants will be asked to consume the provided whey protein enriched breakfast before 1000h daily for 28 days.
Study: NCT04678739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Remdesivir 100 IV Infusion as a lyophilized powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Actemra IV Infusion
Study: NCT03540277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Prevention Program young In Favor of Myself, active parents
Description: Prevention program: young In Favor of Myself, with parent participation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Prevention Program young In Favor of Myself, no parental involvement
Description: Prevention program: young In Favor of Myself, without parent participation
Study: NCT03042403

Intervention type: OTHER
Intervention: Breath stacking
Description: During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
Study: NCT00992342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 5 mg, QD for 14 days
Study: NCT01024361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
Study: NCT01722032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childhood Obesity
Study: NCT02400892

Intervention type: OTHER
Intervention: TTE Bubble Study
Description: Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO

Intervention type: OTHER
Intervention: TTE Bubble Study
Description: Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
Study: NCT00581061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesicare
Description: Vesicare will be taken daily for one or three months, depending on symptoms of subject.
Study: NCT06252467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: Phototherapy treatment (Photobiomodulation therapy or placebo) was performed using a Photobiomodulation therapy device (Vectra Genisys Systems, Chattanooga Group, Dallas, TX, USA). The cluster probe consisted of five low-level laser therapy diodes (850 nm) and 28 light emitting diodes therapy (670 nm, 880 nm, and 950 nm). Photobiomodulation therapy was applied in nine sites of each quadriceps femoris muscle~. A dosage of 15 J per site led to a total energy of 135 J per thigh, effectively increasing cycling performance in a previous study. We chose to apply Photobiomodulation therapy specifically to the quadriceps femoris because this muscle group is of utmost significance in generating torque and propelling the pedaling cycle. Its pivotal role in cycling performance made this muscle a prime target for the Photobiomodulation therapy intervention in our study.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The placebo treatment was performed in exactly the same manner as the Photobiomodulation therapy treatment, but with the device switched off, and the cluster was held stationary in contact with the skin at a 90° angle, with light pressure on the skin. The total application time of Photobiomodulation therapy or placebo was \~5 min for both limbs (9 points per thigh = 18 points × 16 s per point) before each time-to-exhaustion test.
Study: NCT00992342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 15 mg, QD for 14 days
Study: NCT02303834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure Ventilation (CPAP)
Description: A mask worn over the nose that delivers air under slight pressure.
Study: NCT01796301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romozosumab
Description: Administered by subcutaneous injection once a month.
Study: NCT00992342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03893787
Description: oral solution, 50 mg, QD for 14 days
Study: NCT02111863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)
Description: On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
Study: NCT01820884

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TH
Description: Total hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TH/BSO
Description: Total hysterectomy and bilateral salpingo-oophorectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPLND
Description: bilateral pelvic and para-aortic lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BPLND
Description: bilateral pelvic and para-aortic lymph node dissection
Study: NCT02977390

Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raise
Description: By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
Study: NCT02637323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 32 mg
Description: Single 5 mL IA injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA IR 40
Description: Single 1 mL IA injection
Study: NCT00268372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT01796301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: Administered by subcutaneous injection once a day.
Study: NCT01825577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Methylphenidate
Description: 2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
Study: NCT01425177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal Saline Irrigation
Description: After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
Study: NCT03671577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Closer Friendships
Description: Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
Study: NCT02168348

Intervention type: OTHER
Intervention: biological examination at consultations at 3 and 6 months
Study: NCT01882764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given HMPL-004 orally three times per day with total daily dose of 1800 mg for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Remitters and responders from HMPL-004 Induction study and patients complete the 8-week Open Label Induction Phase will be given Placebo orally three times per day with total daily dose of 1800 mg for 52 weeks.